Recombinant Human CDH17 protein, hFc-tagged

• Cat.No.: CDH17-2043H
• Product Overview: Recombinant Human CDH17 protein(Q12864)(Gln23-Met787), fused with C-terminal hFc tag, was expressed in HEK293.

Specification

• Species: Human
• Source: HEK293
• Protein Length: Gln23-Met787
• Tag: C-hFc
• Form: Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Human CDH17, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-CDH17 Antibody, hFc Tag with the EC50 of 8.6ng/ml determined by ELISA.
• Molecular Mass: The protein has a predicted MW of 111.73 kDa. Due to glycosylation, the protein migrates to 113-135 kDa based on Tris-Bis PAGE result.
• Endotoxin: Less than 1EU per μg by the LAL method.
• Purity: > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC.
• Storage: Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Reconstitution: Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Gene Information

• Gene Name: CDH17 cadherin 17, LI cadherin (liver-intestine) [ Homo sapiens ]
• Official Symbol: CDH17
• Synonyms: CDH17; cadherin 17, LI cadherin (liver-intestine); cadherin-17; cadherin; HPT 1; LI cadherin; LI-cadherin; cadherin-16; HPT-1 cadherin; liver-intestine cadherin; human peptide transporter 1; intestinal peptide-associated transporter HPT-1; human intestinal peptide-associated transporter HPT-1; HPT1; CDH16; HPT-1; FLJ26931; MGC138218; MGC142024
• Gene ID: 1015
• mRNA Refseq: NM_001144663
• Protein Refseq: NP_001138135
• MIM: 603017
• UniProt ID: Q12864

Case Study

Case 1: Wang J, et al. Cancer Biol Ther. 2013

Cadherin-17 (CDH17) is a cell adhesion protein predominantly found in the intestines and is associated with poor prognosis in gastric cancer (GC). This study focused on the role of CDH17 in tumorigenesis and lymphatic metastasis in GC. By suppressing CDH17 expression in MKN-45 gastric cancer cells with RNA interference, researchers observed a decrease in cell proliferation, adherence, and invasion, along with cell cycle arrest. This was accompanied by the inactivation of the NFκB signaling pathway and a reduction in downstream proteins like VEGF-C and MMP-9. In vivo tumor growth was significantly inhibited in mice with silenced CDH17 expression, and no lymph node metastasis was detected, contrasting with positive nodes in control groups.

Fig1. Real time RT-PCR indicated that the miR-CDH17 was the optimal sequence, with 80% interference efficacy of CDH17.

Fig2. Less expression of CDH17, nuclear p65, MMP-9 and VEGF-C, but more expression of IκB-α in miR-CDH17 group.

Case 2: Su MC, et al. Mod Pathol. 2008

Cadherin-17, or liver-intestine cadherin, is a cell adhesion glycoprotein primarily expressed in the intestinal epithelium. While it is found in certain adenocarcinomas such as those of the stomach, pancreas, and colon, its diagnostic utility for cancers remains uncertain. The immunohistochemical analysis of tissue arrays revealed cadherin-17 in 96% of colorectal adenocarcinomas, with strong and diffuse staining, and in 25-50% of gastric, pancreatic, and biliary adenocarcinomas. Less than 1% of non-digestive system carcinomas were cadherin-17 positive. Using a two-marker approach with cytokeratin 7, researchers accurately identified 97% of colorectal and 86% of gastrointestinal adenocarcinomas.

Fig1. Western blot analysis of cadherin-17 protein in tissue lysates.

Fig2. Immunohistochemical staining of cadherin-17 in tumor tissue.

Application

Recombinant Human CDH17 protein, also known as Cadherin-17, is a member of the cadherin superfamily of calcium-dependent cell adhesion proteins. It plays a significant role in tumorigenesis and has been identified as a potential therapeutic target in various cancers, including gastric, colorectal, pancreatic, and bladder adenocarcinomas. CDH17 is typically expressed in intestinal epithelial cells and pancreatic excretory ducts but is often overexpressed in certain adenocarcinomas, where it has been linked to metastatic disease and poor prognoses.

In research, recombinant CDH17 protein is used for diagnostic and therapeutic development. It aids in the understanding of its role in cancer progression and as a biomarker for disease presence. The protein's expression levels are analyzed in tissue microarrays, and its function is studied in various cellular assays to explore its potential as a diagnostic marker and therapeutic target.

Clinically, CDH17 is being investigated as a target for immunoPET imaging to visualize CDH17-expressing tumors non-invasively. This could significantly impact the management of patients with CDH17-expressing cancers by providing a tool for more precise and personalized therapies. Additionally, CDH17-targeted therapies, such as antibody-drug conjugates and CAR T-cells, are being developed and tested in preclinical models, showing promise for inhibiting tumor growth.

In summary, recombinant Human CDH17 protein is a valuable asset in the research and potential clinical application for the diagnosis and treatment of CDH17-expressing cancers. Its study contributes to the development of targeted therapies and personalized medicine approaches in oncology.

Fig1. The dorsal subcutaneous xenografted tumor model was used to evaluate the effect of CDH17 on proliferative potency of gastric cancer. (Jin Wang, 2013)